{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T12:17:58Z","timestamp":1685189878508},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,8,6]],"date-time":"2009-08-06T00:00:00Z","timestamp":1249516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00774-009-0112-4","type":"journal-article","created":{"date-parts":[[2009,8,5]],"date-time":"2009-08-05T05:59:58Z","timestamp":1249451998000},"page":"176-184","source":"Crossref","is-referenced-by-count":13,"title":["Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and\/or alfacalcidol in postmenopausal Japanese women"],"prefix":"10.1007","volume":"28","author":[{"given":"Itsuo","family":"Gorai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaku","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Iwaoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,6]]},"reference":[{"key":"112_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","volume":"115","author":"ANA Tosteson","year":"2003","unstructured":"Tosteson ANA, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment for osteoporosis. Am J Inn Med 115:209\u2013216","journal-title":"Am J Inn Med"},{"key":"112_CR2","unstructured":"Eastell R, Garnero P, Vrijens B et al (2003) Influence of patient compliance with residronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72:P297"},{"key":"112_CR3","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-003-1502-4","volume":"14","author":"RA Yood","year":"2003","unstructured":"Yood RA, Emani S, Reed JI et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporosis Int 14:965\u2013968","journal-title":"Osteoporosis Int"},{"key":"112_CR4","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechits KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 15:1003\u20131008","journal-title":"Osteoporosis Int"},{"key":"112_CR5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","volume":"18","author":"JA Cramer","year":"2007","unstructured":"Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis Int 18:1023\u20131031","journal-title":"Osteoporosis Int"},{"key":"112_CR6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s002239900651","volume":"65","author":"I Gorai","year":"1999","unstructured":"Gorai I, Chaki O, Taguchi Y et al (1999) Early postmenopausal bone loss is prevented by estrogen and partially by 1-alpha-OH-vitamin D3: therapeutic effects of estrogen and\/or 1-alpha-OH-vitamin D3. Calcif Tissue Int 65:16\u201322","journal-title":"Calcif Tissue Int"},{"key":"112_CR7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00774-008-0868-y","volume":"26","author":"S O\u2019Donnell","year":"2008","unstructured":"O\u2019Donnell S, Moher D, Thomas K et al (2008) Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab 26:531\u2013542","journal-title":"J Bone Miner Metab"},{"key":"112_CR8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00296-006-0288-z","volume":"27","author":"JD Ringe","year":"2007","unstructured":"Ringe JD, Farahmand P, Schacht E, Rozehnal A (2007) Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 27:425\u2013434","journal-title":"Rheumatol Int"},{"key":"112_CR9","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00198-007-0410-4","volume":"18","author":"F Lekkerkerker","year":"2007","unstructured":"Lekkerkerker F, Kanis JA, Alsayed N et al (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporosis Int 18:1311\u20131317","journal-title":"Osteoporosis Int"},{"key":"112_CR10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s007740170001","volume":"19","author":"H Orimo","year":"2001","unstructured":"Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331\u2013337","journal-title":"J Bone Miner Metab"},{"key":"112_CR11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1172\/JCI118382","volume":"97","author":"CW Slemenda","year":"1996","unstructured":"Slemenda CW, Longcope CL, Peacock M, Hui SL, Johnston CC (1996) Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri- and postmenopausal women. J Clin Invest 97:14\u201321","journal-title":"J Clin Invest"},{"key":"112_CR12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/BF00298428","volume":"57","author":"I Gorai","year":"1995","unstructured":"Gorai I, Chaki O, Nakayama M, Minaguchi H (1995) Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif Tissue Int 57:100\u2013104","journal-title":"Calcif Tissue Int"},{"key":"112_CR13","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/clinchem\/37.9.1534","volume":"37","author":"GF Blackburn","year":"1991","unstructured":"Blackburn GF, Shah HP, Kenten JH, Leland R, Kamin RA, Kink J, Peterman J, Powell MJ, Shah A, Talley DB, Tyagi SK, Wilkins E, Wu T-G, Massey RJ (1991) Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnosis. Clin Chem 37:1534\u20131539","journal-title":"Clin Chem"},{"key":"112_CR14","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/clinchem\/47.4.694","volume":"47","author":"P Garnero","year":"2001","unstructured":"Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694\u2013702","journal-title":"Clin Chem"},{"key":"112_CR15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1210\/jc.2003-030501","volume":"89","author":"JA Clowes","year":"2004","unstructured":"Clowes JA, Peel NFA, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117\u20131123","journal-title":"J Clin Endocrinol Metab"},{"key":"112_CR16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487\u2013497","journal-title":"N Engl J Med"},{"key":"112_CR17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"E Siris","year":"2006","unstructured":"Siris E, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"112_CR18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.curtheres.2005.01.003","volume":"65","author":"JR Zanchetta","year":"2004","unstructured":"Zanchetta JR, Hakim C, Lombas C (2004) Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis. Curr Ther Res Clin Exp 65:470\u2013480","journal-title":"Curr Ther Res Clin Exp"},{"key":"112_CR19","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00198-006-0073-6","volume":"17","author":"M Rossini","year":"2006","unstructured":"Rossini M, Bianchi G, Munno ODi et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporosis Int 17:914\u2013921","journal-title":"Osteoporosis Int"},{"key":"112_CR20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 15:1003\u20131008","journal-title":"Osteoporosis Int"},{"key":"112_CR21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922\u2013928","journal-title":"Bone"},{"key":"112_CR22","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1359\/jbmr.080301","volume":"23","author":"ML Bouxsein","year":"2008","unstructured":"Bouxsein ML, Delmas PD (2008) Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res 23:1155\u20131167","journal-title":"J Bone Miner Res"},{"key":"112_CR23","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.bone.2008.01.021","volume":"42","author":"J-Y Reginster","year":"2008","unstructured":"Reginster J-Y, Collette J, Nerprez A et al (2008) Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 42:832\u2013836","journal-title":"Bone"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-009-0112-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-009-0112-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-009-0112-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T05:30:06Z","timestamp":1590039006000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-009-0112-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,6]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["112"],"URL":"https:\/\/doi.org\/10.1007\/s00774-009-0112-4","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,6]]}}}